Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.
Friedberg
Jonathan W
JW
James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA. jonathan_friedberg@urmc.rochester.edu
D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069461:Bendamustine Hydrochloride; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008495:Medical Oncology / Q000639:trends*; D008942:Mitoxantrone / Q000008:administration & dosage; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage* / Q000627:therapeutic use*; D000069283:Rituximab; D016896:Treatment Outcome
D058846:Antibodies, Monoclonal, Murine-Derived; D009588:Nitrogen Mustard Compounds; D000069283:Rituximab; D000069461:Bendamustine Hydrochloride; D008942:Mitoxantrone